SecBot SecBot
8-K ·Filed Nov 5, 2026

CELC

Celcuity Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed11d 8h ago SEC0001193125-26-449757
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Monitor Q4 2026 for first product revenue recognition and prescription trends; the sNDA for the PIK3CA mutant label expansion is a key catalyst; watch for global regulatory submissions later this year or early next year.

DirectionNeutral
Confidencehigh
Horizonmonths

REVTORPYK

◆ Mixed Named in this 8-K
Impact
Phase
Approved
Time to market
Already approved and commercially available in the US since September 30, 2026. A supplemental NDA (sNDA) for the PIK3CA mutant indication was submitted August 26, 2026; no PDUFA goal date has been publicly confirmed yet.
Next catalyst
None dated

What to watchWatch for the FDA's acceptance and PDUFA goal date for the sNDA covering the PIK3CA mutant indication, which would be the next major regulatory catalyst. Also monitor Q4 2026 earnings (expected early 2027) for the first meaningful product revenue figures and prescription trends. The stock's 126.5% implied upside to the mean analyst target reflects high expectations for commercial execution, so any launch stumbles could pressure the stock further.

Price Chart

Loading chart...

Executive Summary

Celcuity reported Q3 2026 results with no product revenue as REVTORPYK shipments began on Sept 30 and revenue is recognized upon delivery. Net loss widened to $73.3M from $43.8M a year ago, driven by $25.3M in commercial launch costs. The company highlighted strong early launch metrics: 78% of top strategic accounts have ordered, 91% of covered lives have access, and an sNDA for the PIK3CA mutant cohort was submitted.

Key Financial Metrics

EPS (Adj.)
−$1.21
GAAP: $-1.33

Key Facts

  • REVTORPYK (gedatolisib) became commercially available on Sept 30, 2026 for HR+/HER2- PIK3CA wild-type advanced breast cancer
  • No product revenue recognized in Q3 2026 because shipments occurred on Sept 30 and revenue is recognized upon delivery
  • Net loss Q3 2026: $73.3M ($1.33/share) vs $43.8M ($0.92/share) in Q3 2025
  • Non-GAAP adjusted net loss Q3 2026: $66.8M ($1.21/share) vs $37.2M ($0.78/share) in Q3 2025
  • 78% of top 36 strategic accounts (~50% of addressable patients) have ordered REVTORPYK
  • 91% of U.S. commercial and Medicare lives are in health plans that cover REVTORPYK
  • Cash, cash equivalents and short-term investments: $642.7M at Sept 30, 2026; expected to fund operations through 2029
  • sNDA submitted to FDA in Q3 2026 for PIK3CA mutant cohort based on positive Phase 3 VIKTORIA-1 data
  • FDA approved REVTORPYK on July 14, 2026; NCCN gave preferred Category 1 recommendation on July 30, 2026
  • Made $50M milestone payment to Pfizer triggered by FDA approval

Financial Impact

No product revenue in Q3; net loss $73.3M vs $43.8M YoY; cash burn $66.2M operating cash flow; $642.7M cash runway through 2029

revenuenet lossoperating expensescash position

Risk Factors

  • No product revenue yet; launch revenue trajectory uncertain
  • Operating expenses surged 81% YoY to $77.3M as commercial infrastructure builds out
  • Stockholders' equity turned negative ($74M deficit) due to accumulated losses and convertible note accounting
  • sNDA for PIK3CA mutant cohort under FDA review; approval not guaranteed
  • Dependence on single product REVTORPYK for near-term revenue

Market Snapshot

Exchange
Nasdaq
Sector
Services-Medical Laboratories
Analyst Consensus
95% bullish (19 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-449757
Document: celc-20261105.htm0001193125-26-449757
Document: 0001193125-26-449757-index-headers.html0001193125-26-449757
Document: 0001193125-26-449757-index.html0001193125-26-449757
Document: 0001193125-26-449757.txt0001193125-26-449757
8-K Data (Synthetic)0001193125-26-449757

Track record

26 reports on CELC

Performance horizon

7 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +26.84% at T+20 after the Jun 11, 2026 report. 9 of 13 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $62.58 Now $60.57 −3.21% settles Nov 23
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $64.37 Now $60.57 −5.90% settles Nov 23
  3. Nov 9, 20267d ago Press Release Bullish 5/10 Entry $70.37 to $60.57 Now $60.57 −13.93% ▼ −13.93% −12.23% vs SPY
  4. Nov 5, 202611d ago 8-K Neutral 5/10 Viewing No price data
  5. Nov 5, 202611d ago Press Release Neutral 5/10 Entry $66.79 to $64.37 Now $60.57 −9.31% ▼ −3.62% −6.22% vs SPY
  6. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $69.72 to $67.05 Now $60.57 −13.12% ▼ −3.83% −3.24% vs SPY
  7. Oct 24, 202623d ago Press Release Bullish 6/10 Entry $65.80 to $69.13 Now $60.57 −7.95% ▲ +5.06% +6.32% vs SPY
  8. Oct 5, 20266w ago 3 Neutral 2/10 Entry $71.25 to $63.19 Now $60.57 −14.99% ▼ −11.31% −11.17% vs SPY
  9. Oct 2, 20266w ago 8-K Neutral 2/10 Entry $72.10 to $67.94 Now $60.57 −15.99% ▼ −5.77% −6.93% vs SPY
  10. Sep 30, 20266w ago 8-K Bullish 6/10 Entry $79.52 to $65.78 Now $60.57 −23.83% ▼ −17.28% −19.19% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens in 8h 27m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026